Difference between revisions of "Dacarbazine (DTIC)"
Jump to navigation
Jump to search
m |
m (→References) |
||
| Line 33: | Line 33: | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
[[Category:DNA synthesis inhibitors]] | [[Category:DNA synthesis inhibitors]] | ||
| + | [[Category:Antimetabolites]] | ||
[[Category:Purine analogues]] | [[Category:Purine analogues]] | ||
Revision as of 20:42, 11 December 2014
General information
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Melanoma
- Neuroendocrine tumors
- Sarcoma
Patient drug information
- Dacarbazine (DTIC) patient drug information (Chemocare)[3]
- Dacarbazine (DTIC) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/27/1975: Initial FDA approval
Also known as
DIC, DTIC-Dome, Imidazole carboxamide
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Irritant chemotherapy
- Alkylating agents
- DNA synthesis inhibitors
- Antimetabolites
- Purine analogues
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Melanoma medications
- Neuroendocrine tumor medications
- Sarcoma medications
- Drugs FDA approved in 1975